An AI model integrating digitized slide images, clinical data, and a 42-gene panel provides superior prognostic accuracy for early, late, and overall breast cancer recurrence compared to using the 21-gene score alone. This multimodal approach represents the future of risk assessment.
The SET assay, measuring estrogen receptor activity, re-analyzed the NSABP B42 trial and found a 'very high SET' subgroup. This group experienced a massive 17% absolute improvement in 10-year breast cancer-free interval with extended letrozole, unmasking a profound benefit that was diluted in the overall trial results.
Data from the FLEX registry trial, supported by propensity score matching, indicates the survival benefit of adding anthracycline (Adriamycin) to chemotherapy is confined to patients with a MammaPrint High 2 (ultra-high risk) score. Patients in the High 1 group saw no additional benefit.
Counterintuitively, the SOFT trial showed pre-menopausal women with BCI-low tumors (less driven by estrogen receptors) derived more benefit from an aromatase inhibitor (AI) plus ovarian suppression compared to tamoxifen. This suggests the most aggressive endocrine therapy is crucial for biologically aggressive, less ER-sensitive cancers.
A registry trial of 3,000 women showed that BCI results caused physicians to change their initial recommendations for or against extended endocrine therapy in 41% of cases. The genomic test also significantly increased patient confidence in their treatment decisions, demonstrating its real-world utility in shared decision-making.
An analysis of the RxPONDER trial found that while Black women had worse outcomes despite similar genomic scores and treatment, adjusting for Body Mass Index (BMI) attenuated this disparity from a 50% worse outcome to a non-significant 15%. This suggests comorbidities are critical drivers of racial outcome differences.